What is the prognosis for patients with IDH2 mutations?
The prognosis for patients with IDH2 mutations can vary depending on the type of cancer and the presence of other genetic abnormalities. In AML, patients with IDH2 mutations often have a distinct clinical profile and may respond well to IDH2 inhibitors. However, the overall prognosis depends on various factors, including the patient's age, overall health, and response to treatment.
